Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;68(1):48-52.
doi: 10.1016/S0377-1237(11)60120-2. Epub 2012 Jan 18.

Evaluation of bone mineral density in type 2 diabetes mellitus patients before and after treatment

Mk Dutta  1 , R Pakhetra  2 , Mk Garg  3
Affiliations

Evaluation of bone mineral density in type 2 diabetes mellitus patients before and after treatment

Mk Dutta et al. Med J Armed Forces India. 2012 Jan.

Abstract

Background: The relationship between bone mineral density (BMD) and type 2 diabetes mellitus (T2DM) has been controversial. Recent studies have revealed adverse impact of antidiabetic drugs on BMD in type 2 diabetic patients. However, the influence of various antihyperglycaemic agents on BMD has not been well studied.

Method: A total of 200 patients with T2DM were screened initially for the study. Finally 67 patients (M:34, F:33) who satisfied the requirement of having been on one year of prescribed therapy were included for analysis.

Results: Bone mineral density was lower in diabetic patients as compared to controls (hip 0.962 ± 0.167 g/cm(2) vs 1.013 ± 0.184 g/cm(2), P = 0.05; spine 0.929 ± 0.214 g/cm(2) vs 1.113 ± 0.186 g/cm(2), P < 0.00001). In males BMD was significantly lower at spine (P < 0.00001) and in females BMD was significantly lower in both at the spine (P < 0.00001) and hip (P < 0.032). On multivariate analysis significant positive correlation was found between spine BMD and body mass index (BMI) (r = 0.372, P = 0.002), total cholesterol (r = 0.272, P = 0.026), low-density lipoprotein (r = 0.242, P = 0.047), and triglycerides (r = 0.282, P = 0.021). There was no correlation between BMD and glycosylated haemoglobin (r = 0.158, P = 0.265). A significant decrease in BMD at spine and hip was seen with the use of glitazones and metformin while increase was noted with sulphonylurea and its combination.

Conclusion: Men and women with T2DM have lower BMD. Bone mineral density did not have correlation to glycaemic control. Glitazones, metformin, and insulin are associated with decrease in BMD at spine, and hip, while sulphonylureas are associated with increase in BMD.

Keywords: antihyperglycaemic drugs; bone mineral density; type 2 diabetes mellitus.

PubMed Disclaimer

References

    1. Al-Zaabi K, Badr HE, Mahussain S, Mohammad M, Al-Nafisi N. Bone mass density in diabetic women: is there a detrimental effect? Middle East J Age Aging. 2008;5:12–17.
    1. Sosa M, Dominguez M, Navarro MC. Bone mineral metabolism is normal in non-insulin-dependent diabetes mellitus. J Diabetes Complications. 1996;10:201–205. - PubMed
    1. Hadzibegovic I, Miskic B, Cosic V, Prvulovic D, Bistrovic D. Increased bone density in postmenopausal women with type 2 diabetes mellitus. Ann Saudi Med. 2008;28:102–104. - PMC - PubMed
    1. Dennison EM, Syddall HE, Aihie Sayer A, Craighead S, Phillips DI, Cooper C. Type 2 diabetes mellitus is associated with increased axial bone density in men and women from the Hertfordshire Cohort Study: evidence for an indirect effect of insulin resistance? Diabetologia. 2004;47:1963–1968. - PubMed
    1. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008;168:820–825. - PubMed

LinkOut - more resources